Review papers with raw data transparency

Visual summary of coverage: mechanisms emphasized

Key strengths (visual then bullets)

• Broad, current synthesis: integrates chromatin-focused lncRNAs (HOTAIR, PANDAR), triplex-formers (MEG3, MIR100HG), LLPS drivers (NEAT1), ceRNA networks (TINCR, SNHG7), and translational strategies (ASO, CRISPRi, small-molecule structure targeting) Sideris et al. (review)
• Mechanism-to-therapy logic: explains why low expression and cell-type specificity favour nucleic-acid or structure-directed approaches, and cites in vivo preclinical successes (e.g., MALAT1/HOTAIR targeting) Therapeutic examples in review
• Good methodological signposting: enumerates experimental methods used in cited work (CHIRP/CHART, RIP, ChIP-seq, Hi-CHiP, ATAC-seq, CHiA-PET) which helps readers locate primary evidence.

Main limitations & blindspots (visual + concise bullets)

• No systematic search / selection bias: authors state a literature survey approach; lack of pre-registered search raises selection bias and publication-bias risk Narrative review design
• Heterogeneous evidence quality: paper combines detailed mechanistic cell/xenograft studies with correlative human/TCGA-based reports; such aggregation risks overgeneralizing model-specific findings (authors acknowledge conservation/modeling issues) Model heterogeneity note
• Limited negative/replication discussion: scarce attention to contradictory or null reports; for example, MALAT1 has context-dependent results across studies (oncogenic vs dispensable in some genetic models) and should be balanced by citing negative/replication work (not emphasized here).
• Translational gaps underplayed: the paper mentions delivery and immunogenicity problems but does not deeply evaluate translational failure modes, regulatory barriers, or clinical trial readiness for lncRNA therapeutics.

Critical appraisal: claims & underlying evidence (select examples)

1. HOTAIR — chromatin reprogramming & metastasis: review cites foundational mechanistic evidence for HOTAIR guiding PRC2 to alter chromatin and for its association with metastasis; this claim is supported by high-impact primary work but subsequent replication/clinical utility remain context-dependent Gupta et al. HOTAIR Nature
2. NEAT1 / LLPS — paraspeckle architecture and disease links: review correctly emphasises NEAT1 as an architectural lncRNA enabling paraspeckle assembly and links to phase separation; strong biochemical/visualization evidence exists, though cancer-causation remains associative in many datasets NEAT1 paraspeckle paper
3. Triplexes (MEG3, MIR100HG): review cites primary CHIRP/CHART/biochemical data showing RNA–DNA triplex formation at specific promoters (MEG3 at TGFR1, MIR100HG at p27); these are mechanistically plausible but require broader validation across contexts MEG3 triplex evidence
4. Therapeutic targeting (ASOs, small molecules): review references preclinical successes (ASOs against MALAT1/HOTAIR; small molecule AC1Q3QWB disrupting HOTAIR-PRC2). These are valid early proofs-of-principle, but clinical translation faces delivery, specificity, immunogenicity, and off-target hurdles emphasized in the review and the broader literature AC1Q3QWB small-molecule study

Where the review could be improved (concise, actionable)

• Include a transparent literature-selection statement (databases searched, dates, inclusion/exclusion) or convert to a systematic scoping supplement.
• Integrate a simple evidence-level table for major lncRNAs (human cohort association, independent replication, orthogonal mechanistic assays, in vivo validation) so readers can weigh robustness at a glance.
• More explicit discussion of null/contradictory data (e.g., MALAT1 conditional models vs earlier knockdown studies) to prevent overconfidence in translational claims.
• Highlight key roadblocks to clinical translation with quantitative metrics (e.g., ASO biodistribution, immunogenicity rates, required fold-change for biomarker sensitivity/specifity) referencing the primary drug-delivery literature.

Conclusions & confidence

Sideris et al. (2022) provides a timely, comprehensive narrative synthesis of lncRNA mechanisms in breast cancer and translational opportunities. It is highly useful as a conceptual map and for readers new to the lncRNA–oncology interface. However, because the review is narrative rather than systematic and mixes evidence levels without a formal grading, its translational optimism should be interpreted cautiously; many promising preclinical findings still lack robust, multi-cohort clinical validation and face delivery/biostability barriers. Confidence in the review's descriptive claims is moderate-to-high for mechanism summaries, but low-to-moderate for clinical readiness assertions (see inline evidence above).

Immediate, practical next-steps (for researchers reading the review)

1. Run focused CRISPRi or CRISPRa pooled screens in patient-derived organoids (subtype-stratified) to validate lncRNA loci identified in the review and in TCGA-based signatures (link screens to single-cell readouts) CRISPRi screen reference
2. Standardize a 4-column evidence table per lncRNA: (1) human-association (cohort+effect), (2) orthogonal molecular mechanism, (3) in vivo functional validation, (4) therapeutic tractability (ASO/structure/small-molecule evidence).
3. Prioritise lncRNAs for translational development that (a) show human prognostic association in multiple cohorts, (b) have orthogonal mechanistic evidence, and (c) demonstrate tractability to ASOs or small molecules in xenografts (e.g., PVT1, HOTAIR, NEAT1 candidates discussed).